Elevai Labs Inc. announced the establishment of two new wholly owned subsidiaries, Elevai Biosciences Inc., and Elevai Skincare Inc. These ventures mark a strategic shift towards the development of next-generation aesthetic medicines and efforts to improve the economics of its commercialized exosome skincare brand. This subsidiary will focus on the development and acquisition of cutting-edge aesthetic medicines, underscoring Elevai?s commitment to innovation and its vision to lead the evolution of the medical aesthetics industry. Leveraging advanced research and strategic acquisitions, Elevai Biosciences aims to pioneer breakthroughs in aesthetic medicine.

Elevai Biosciences? lead asset, EL-22, will target muscle mass preservation in the obesity market with a novel myostatin approach that is planned to be tested in combination with popular weight loss drugs, including GLP-1 receptor agonists. Simultaneously, Elevai is transitioning its commercialized exosome skincare brand and operations into Elevai Skincare Inc., its subsidiary dedicated to advancing Elevai?s skincare solutions.

By reorganizing skincare operations into a separate entity, Elevai aims to enhance focus, agility and market penetration. The restructuring will position Elevai Skincare for accelerated growth and profitability, in order to capitalize on emerging opportunities in the medical aesthetics skincare market.